GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shanxi C&Y Pharmaceutical Group Co Ltd (SZSE:300254) » Definitions » Piotroski F-Score

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Piotroski F-Score : 7 (As of May. 26, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score?

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanxi C&Y Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SZSE:300254' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 5   Max: 8
Current: 7

During the past 13 years, the highest Piotroski F-Score of Shanxi C&Y Pharmaceutical Group Co was 8. The lowest was 2. And the median was 5.


Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score Historical Data

The historical data trend for Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score Chart

Shanxi C&Y Pharmaceutical Group Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 2.00 7.00 4.00 6.00

Shanxi C&Y Pharmaceutical Group Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 5.00 6.00 7.00

Competitive Comparison of Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar24) TTM:Last Year (Mar23) TTM:
Net Income was -21.965 + 10.431 + 38.887 + 18.284 = ¥45.6 Mil.
Cash Flow from Operations was 7.184 + 10.218 + 26.977 + 35.486 = ¥79.9 Mil.
Revenue was 182.396 + 206.358 + 227.366 + 189.493 = ¥805.6 Mil.
Gross Profit was 120.354 + 144.314 + 155.273 + 124.988 = ¥544.9 Mil.
Average Total Assets from the begining of this year (Mar23)
to the end of this year (Mar24) was
(1644.517 + 1672.336 + 1470.727 + 1433.075 + 1476.234) / 5 = ¥1539.3778 Mil.
Total Assets at the begining of this year (Mar23) was ¥1,644.5 Mil.
Long-Term Debt & Capital Lease Obligation was ¥155.3 Mil.
Total Current Assets was ¥417.3 Mil.
Total Current Liabilities was ¥447.2 Mil.
Net Income was -21.285 + -2.546 + -93.149 + -2.157 = ¥-119.1 Mil.

Revenue was 213.223 + 228.897 + 195.142 + 183.185 = ¥820.4 Mil.
Gross Profit was 146.168 + 159.524 + 135.686 + 121.891 = ¥563.3 Mil.
Average Total Assets from the begining of last year (Mar22)
to the end of last year (Mar23) was
(1530.572 + 1597.546 + 1648.94 + 1584.408 + 1644.517) / 5 = ¥1601.1966 Mil.
Total Assets at the begining of last year (Mar22) was ¥1,530.6 Mil.
Long-Term Debt & Capital Lease Obligation was ¥186.7 Mil.
Total Current Assets was ¥576.3 Mil.
Total Current Liabilities was ¥666.7 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanxi C&Y Pharmaceutical Group Co's current Net Income (TTM) was 45.6. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Shanxi C&Y Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 79.9. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar23)
=45.637/1644.517
=0.02775101

ROA (Last Year)=Net Income/Total Assets (Mar22)
=-119.137/1530.572
=-0.07783822

Shanxi C&Y Pharmaceutical Group Co's return on assets of this year was 0.02775101. Shanxi C&Y Pharmaceutical Group Co's return on assets of last year was -0.07783822. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Shanxi C&Y Pharmaceutical Group Co's current Net Income (TTM) was 45.6. Shanxi C&Y Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 79.9. ==> 79.9 > 45.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar23 to Mar24
=155.339/1539.3778
=0.10091025

Gearing (Last Year: Mar23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar22 to Mar23
=186.655/1601.1966
=0.11657219

Shanxi C&Y Pharmaceutical Group Co's gearing of this year was 0.10091025. Shanxi C&Y Pharmaceutical Group Co's gearing of last year was 0.11657219. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar24)=Total Current Assets/Total Current Liabilities
=417.256/447.218
=0.93300359

Current Ratio (Last Year: Mar23)=Total Current Assets/Total Current Liabilities
=576.327/666.67
=0.86448618

Shanxi C&Y Pharmaceutical Group Co's current ratio of this year was 0.93300359. Shanxi C&Y Pharmaceutical Group Co's current ratio of last year was 0.86448618. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Shanxi C&Y Pharmaceutical Group Co's number of shares in issue this year was 241.537. Shanxi C&Y Pharmaceutical Group Co's number of shares in issue last year was 242.338. ==> There is smaller number of shares in issue this year, or the same. ==> Score 1.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=544.929/805.613
=0.67641535

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=563.269/820.447
=0.68653917

Shanxi C&Y Pharmaceutical Group Co's gross margin of this year was 0.67641535. Shanxi C&Y Pharmaceutical Group Co's gross margin of last year was 0.68653917. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar23)
=805.613/1644.517
=0.48987818

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar22)
=820.447/1530.572
=0.53603947

Shanxi C&Y Pharmaceutical Group Co's asset turnover of this year was 0.48987818. Shanxi C&Y Pharmaceutical Group Co's asset turnover of last year was 0.53603947. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+1+1+1+0+0
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Shanxi C&Y Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Shanxi C&Y Pharmaceutical Group Co  (SZSE:300254) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Shanxi C&Y Pharmaceutical Group Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Shanxi C&Y Pharmaceutical Group Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Business Description

Traded in Other Exchanges
N/A
Address
No.53, Hubin Street, Economic and Technological Development Zone, Datong, CHN, 037010
Shanxi C&Y Pharmaceutical Group Co Ltd is engaged in the production, research and development, and sales of pharmaceutical products. The company offers pregnancy products and services, anti-infective, and urinary health.
Executives
Zuo Xue Min Supervisors
Huang Le Qun Director
Zhang Zhen Biao Executives
Yu Jun Xian Directors, Directors, and Executives
Zhao Qun Director
Weng Zhan Guo Director
Geng Chun Feng Director
Pang Xiao Quan Supervisors
Zhong Hai Rong Directors, executives
Xuan Hang Director

Shanxi C&Y Pharmaceutical Group Co (SZSE:300254) Headlines

No Headlines